Last reviewed · How we verify

Cook County Health — Portfolio Competitive Intelligence Brief

Cook County Health pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NPH insulin and regular insulin NPH insulin and regular insulin marketed
Glipizide XL Glipizide XL marketed
Non-medicated patch Non-medicated patch marketed
Glipizide and Glargine Glipizide and Glargine marketed Insulin secretagogue + Long-acting insulin ATP-sensitive potassium channel (glipizide); Insulin receptor (glargine) Diabetes
Warfarin and Enoxaparin Warfarin and Enoxaparin marketed Anticoagulant combination (vitamin K antagonist + low-molecular-weight heparin) Vitamin K-dependent clotting factors (warfarin); Factor Xa and Factor IIa (enoxaparin) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Cook County Health:

Cite this brief

Drug Landscape (2026). Cook County Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cook-county-health. Accessed 2026-05-16.

Related